A Study of EMB-02 in Participants With Advanced Solid Tumors

Inclusion Criteria:

• Willing and able to provide written informed consent.

• Phase I: Patients with histologically or cytologically confirmed locallyadvanced/metastatic solid tumors and have failed (progressed on, or are intolerantof) standard therapies. Moreover, the disease should be measurable or evaluable perRECIST v1.1

• Phase II Cohort A: Patients with histologically or cytologically confirmed locallyadvanced/metastatic melanoma, excluding uveal melanoma. > 1 prior therapy, includingprior treatment with PD-1/L1(mandatory) and/or CTLA-4 inhibitors(optional). And thedisease is measurable or evaluable per RECIST v1.1

• Archival tumor samples available for retrospective analysis or biopsy will be taken.

• ECOG performance status 0 or 1 for phase I, and ≤2 for phase II; life expectancy > 3Months

• Adequate organ function to participate in the trial.

• Recovery from adverse events (AEs) related to prior anticancer therapy.

• Highly effective contraception

Exclusion Criteria:

• Patients who have active autoimmune disease or history of autoimmune disease

• History of severe irAE.

• History of severe allergic reactions

• Use of systemic corticosteroids.

• Symptomatic central nervous system metastases.

• Patients with cardiac dysfunction

• Uncontrolled diabetes mellitus with hemoglobin A1c > 8% (via medical history)

• Prior treatment with a LAG-3 inhibitor

• Anticancer therapy or radiation < 5 half-lives or 4 weeks (whichever is shorter)prior to study treatment;

• Prior organ or stem cell/bone marrow transplant.

• Concurrent malignancy < 5 years prior to entry.

• Patients with active infections.

• Major surgery < 4 weeks or minor surgery < 2 weeks prior to study treatment

• Live virus vaccines < 30 days prior to screening

• Pregnant or breast-feeding females

• Any investigational agents or study drugs from a previous clinical study within 30days of the first dose of study treatment

• Any other serious underlying medical conditions

• Abuse on alcohol, cannabis- derived products or other drugs